Centers for Disease Control and Prevention

NIOSH HSRB

Date received



Signature Page for Human Research Review Protocols and Related Documentation

Use this signature page when submitting HRPO forms to your center-level Human Subjects Contact. When submitting materials with these forms, please consecutively number all pages, beginning with the protocol title page and followed by consent form(s) and ancillary documents. See HRPO Guide: Overview for further details. NOTE: IRB (Institutional Review Board) refers to the NIOSH HSRB (National Institute for Occupational Safety and Health (NIOSH) Human Subjects Review Board (HSRB) of the CDC Human Research Protection Office (HRPO).

1	Protocol identifiers		CAN#		(optional)	
	Leave protocol ID blank i	f not yet assigned.	D	1		
	CDC protocol ID:	otation Devices and Commerc		l version number		
	Use	otation Devices and Commerc	iai Fisheimen. Fi	econceptions an	u Evaluations in Actual	
	Amendment number (if ap	pplicable):				
2	Key CDC personnel					
		Name and degrees (FirstName LastName, Degrees)	User ID	SEV#	CDC NC/division	
	Primary contact (required)	Jennifer Lincoln, PhD	jxw7	8443	NIOSH/OD/AFS	
	Principal investigator (required)	Jennifer Lincoln, PhD	jxw7	8443	NIOSH/OD/AFS	
		c Ethics Verification Number. coordinating center or office is			center or equivalent and	
3		ed with this signatu				
3		ed with this signatu				
3	Forms submitte	ed with this signatue appropriate column.				
3	Forms submittee Check all that apply in the	ed with this signature appropriate column.	ure page Exempted pro		r Exemption	
3	Forms submittee Check all that apply in the IRB-reviewed protocols 0.1250: Initial Review	ed with this signature appropriate column.	Exempted pro	otocols nitial Review fo	r Exemption ew of Exempted Protocol	
3	Forms submittee Check all that apply in the IRB-reviewed protocols ☑ 0.1250: Initial Review ☐ 0.1251: Continuing Re	ed with this signature appropriate column. by by IRB	Exempted pro 0.1250X: In 0.1251X: C	otocols nitial Review fo Continuing Revi		
3	Forms submittee Check all that apply in the IRB-reviewed protocols ☑ 0.1250: Initial Review ☐ 0.1251: Continuing Re	ed with this signature appropriate column. by JRB eview of Approved Protocol anges to Approved Protocol	Exempted pro 0.1250X: In 0.1251X: C	otocols nitial Review fo Continuing Revi	ew of Exempted Protocol	
3	Forms submittee Check all that apply in the IRB-reviewed protocols 0.1250: Initial Review 0.1251: Continuing Re 0.1252: Review of Che 0.1254: Incident Repo	ed with this signature appropriate column. by JRB eview of Approved Protocol anges to Approved Protocol	Exempted pro 0.1250X: In 0.1251X: C	otocols nitial Review fo Continuing Revi	ew of Exempted Protocol	
3	Forms submittee Check all that apply in the IRB-reviewed protocols 0.1250: Initial Review 0.1251: Continuing Re 0.1252: Review of Che 0.1254: Incident Repo	ed with this signature appropriate column. by IRB eview of Approved Protocol anges to Approved Protocol ort al Adverse Event Report	Exempted pro 0.1250X: In 0.1251X: C	otocols nitial Review fo Continuing Revi	ew of Exempted Protocol ges to Exempted Protocol	
3	Forms submittee Check all that apply in the IRB-reviewed protocols ☑ 0.1250: Initial Review ☐ 0.1251: Continuing Re ☐ 0.1252: Review of Che ☐ 0.1254: Incident Repo ☐ 0.1254S: Supplementa	e appropriate column. by JRB eview of Approved Protocol anges to Approved Protocol ort al Adverse Event Report n Research Review	Exempted pro 0.1250X: In 0.1251X: C 0.1252X: R	otocols nitial Review fo Continuing Revi Review of Chang	ew of Exempted Protocol ges to Exempted Protocol search Review	
3	Forms submittee Check all that apply in the IRB-reviewed protocols 0.1250: Initial Review 0.1251: Continuing Re 0.1252: Review of Che 0.1254: Incident Repo 0.1254S: Supplementa 0.1253: End of Human	e appropriate column. by IRB eview of Approved Protocol anges to Approved Protocol ort al Adverse Event Report in Research Review in Partners	Exempted pro 0.1250X: In 0.1251X: C 0.1252X: R	otocols nitial Review fo Continuing Revi Review of Chang d of Human Res	ew of Exempted Protocol ges to Exempted Protocol search Review	
3	Forms submittee Check all that apply in the IRB-reviewed protocols ☑ 0.1250: Initial Review ☐ 0.1251: Continuing Re ☐ 0.1252: Review of Che ☐ 0.1254: Incident Repo ☐ 0.1254S: Supplementa ☐ 0.1253: End of Human ☐ 0.1370: CDC's Resean ☐ 0.1371: CDC Rely on	e appropriate column. by IRB eview of Approved Protocol anges to Approved Protocol ort al Adverse Event Report in Research Review in Partners	Exempted pro 0.1250X: In 0.1251X: C 0.1252X: R	otocols nitial Review fo Continuing Revi Review of Chang d of Human Res	ew of Exempted Protocol ges to Exempted Protocol search Review	

4 Signatures

As principal investigator, I hereby accept responsibility for conducting this CDC-sponsored research project in an ethical manner, consistent with the policies and procedures contained in CDC's *Procedures for Protection of Human Research Participants*, and to abide by the principles outlined in federal policies for the protection of human subjects at 45 CFR part 46, 21 CFR part 50, and 21 CFR part 56.

Signature
Principal CDC Investigator:

J-4-08

As a supervisor of the principal investigator, I hereby accept responsibility for ensuring that this CDC-sponsored research project is conducted in an ethical manner, consistent with the policies and procedures contained in CDC's *Procedures for Protection of Human Research Participants*, and to abide by the principles outlined in federal policies for the protection of human subjects at 45 CFR part 46, 21 CFR part 50, and 21 CFR part 56.

I concur that this CDC-sponsored research project is consistent with the policies and procedures contained in CDC's *Procedures for Protection of Human Research Participants* and with other applicable CDC and national center policies.

Signature
Chair, NIOSH HSRB:

Other Clearance Official:
(e.g., Confidentiality Officer, Coordinating Center/Office Official)

5 Additional comments

6 Reminder regarding other regulatory clearance processes

The principal investigator is responsible for obtaining other regulatory reviews as needed, which may include OMB clearance under the Paperwork Reduction Act (PRA) for federally sponsored information collections. Approval by or exemption from the IRB is unrelated to OMB clearance requirements under the PRA. For more information on whether your study requires clearance under PRA or other regulations, please consult the appropriate officials within your national center.

52